So all released in the last two weeks. One day the market will take notice:
Bell Potter, valuation $2.31
"We continue to believe there are multiple developers that may acquire VLA to secure the exclusive right to Cavatak. We believe the Keynote 200 data has the potential to attract further international attention."
Edison, valuation $1.95
"The four new Phase I studies planned for FY18 (uveal melanoma, head and neck cancer, metastatic colorectal cancer and iv administration in melanoma) will generate considerable information about the potential breadth of application of Cavatak, which is also likely to be of considerable interest to potential partners."
"Given the positive signs of efficacy to date, prospects for attracting a big pharma partner appear promising."
Bioshares
"As the positive results continue and the utility of this therapy as a necessary treatment option in oncology is confirmed, particularly with improving the effectiveness of checkpoint inhibitors, there is a good chance that Viralytics will become a takeover target in 2018."
